• Vimy Pharmaceuticals reached a definitive deal to combine with TSXV-listed Harmony Acquisitions Corp., with Harmony set to be renamed Vimy Pharmaceuticals.
• Harmony will acquire Vimy via a three-cornered amalgamation, exchanging one Resulting Issuer share for each Vimy Pharma share.
• Completion is targeted for late October 2026, with an outside date of Nov. 30, 2026.
• Post-close share count expected at 31,520,296, with 86.19% held by existing Vimy holders and 12.75% by financing subscribers.
• Transaction includes a $625,000 finder’s fee to Triforce Ventures SA, payable in shares priced at $3.00.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Acquisitions Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609280927NEWSFILECNPR____20260928_315849_1) on September 28, 2026, and is solely responsible for the information contained therein.